An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Trial Profile

An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Expanded access
  • Acronyms ACCESS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.
    • 05 Nov 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov record
    • 05 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top